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A novel alternative splicing form of excitatory amino acid
transporter 1 is a negative regulator of glutamate uptake
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Abstract
EAAT1 is a major glutamate transporter in the CNS and is
required for normal neurotransmission and neuroprotection
from excitotoxicity. In the present study, we have identiﬁed a
novel form of the human EAAT1, named here as EAA-
T1ex9skip, which lacks the entire exon 9. Quantitative PCR
analysis indicates that this variant is expressed throughout the
CNS, both in grey matter and axonal tracts, at levels ranging
between 10% and 20% of the full-length EAAT1 form. When
expressed in HEK293 cells, EAAT1ex9skip mRNA is trans-
lated into a truncated protein localized in the endoplasmic
reticulum. EAAT1ex9skip has no functional glutamate uptake
activity but instead, exerts a dominant negative effect over full-
length EAAT1 function. In turn, co-expression of full-length
EAAT1 and EAAT1ex9skip variants reduces the insertion of
the former into the plasma membrane. Together, these results
indicate that the EAAT1ex9skip splice variant is a negative
regulator of full-length EAAT1 function in the human brain.
Keywords: EAAT1ex9skip, glutamate aspartate transporter,
splice variant.
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High afﬁnity glutamate uptake constitutes the major mech-
anism by which glutamate homeostasis is preserved in the
CNS, protecting neurones and oligodendrocytes from glu-
tamate excitotoxic death due to the excessive activation of
glutamate receptors (Choi 1992; Matute et al. 1997). Many
neurodegenerative conditions, including Parkinson’s disease,
Alzheimer’s disease, cerebral ischemia, traumatic brain
injury, epilepsy, Huntington’s chorea, amyotrophic lateral
sclerosis, schizophrenia and multiple sclerosis, have been
linked to disturbed glutamate homeostasis (Danbolt 2001;
Matute et al. 2001, 2005). Glutamate transporters also play
an important role in synapses, where they modulate postsy-
naptic responses and contribute to glutamate recycling into
presynaptic terminals (Danbolt 2001). Glutamate transporters
are plasma membrane glycoproteins composed of eight
transmembrane domains that are proposed to assemble as
homomultimers (Haugeto et al. 1996; Eskandari et al. 2000;
Grunewald and Kanner 2000; Seal et al. 2000). To date, ﬁve
human glutamate transporter subtypes have been cloned
(EAAT1–5) (Shashidharan and Plaitakis 1993; Arriza et al.
1994; Fairman et al. 1995; Arriza et al. 1997). In particular,
glial EAAT1 and EAAT2 have the greatest impact on
glutamate clearance in the CNS (Rothstein et al. 1996) and
thus, they are essential for normal neurotransmission and
protection from excitotoxicity.
Alternative splicing of RNA is a common mechanism that
allows for the diversiﬁcation of a single gene into different
protein products (Lopez 1998). Recently, alternative splicing
has begun to be considered as one of the most important
mechanisms regulating gene expression. This is due to the
fact that this highly versatile mechanism can regulate not
only the amount of mRNA but primarily, these changes in
protein sequence can affect almost all aspects of protein
function, such as binding properties, protein stability,
enzymatic activity, post-translational modiﬁcations and intra-
cellular localization (Stamm et al. 2005).
Previous studies report the existence of several human
EAAT2 and EAAT3 splice variants (Lin et al. 1998; Nagai
et al. 1998; Matsumoto et al. 1999; Meyer et al. 1999). Most
of these variants have little or no glutamate transport activity,
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processing of full-length glutamate transporters.
In the present study, we report the identiﬁcation of a novel,
alternatively spliced EAAT1 mRNA, expressed in human
brain, that we have named EAAT1ex9skip. While there are
previous reports of one splice variant of glutamate aspartate
transporter (GLAST), which is the rat EAAT1 homologue
(Huggett et al. 2000, 2002), this is the ﬁrst report of a human
EAAT1 splice product to date. We have analysed the
expression and function of EAAT1ex9skip at RNA and
protein level to understand further the role of glutamate
transporter splicing variants and their interaction with the
full-length proteins. Our experiments show that EAAT1ex9s-
kip is retained in the endoplasmic reticulum (ER) and
modulates the functional properties of full length EAAT1 in a
dominant-negative way.
Materials and methods
Human brain tissue
Control human tissue used in this study was collected with
appropriate autopsy consent procedures (Hospital de Cruces, Bilbao,
Spain). Brain regions were dissected according to functional and
anatomic regions. At autopsy, tissues were frozen with dry ice and
stored at )80 C until use.
RT-PCR analysis of EAAT1 mRNA in human CNS
Total RNAwas extracted with Trizol reagent (Invitrogen, Barcelona,
Spain), and cDNA was synthesized using random hexamers and
Superscript III reverse transcriptase (Invitrogen), following the
manufacturer’s instructions. Primers used for PCR (Genotek,
Sabadell, Spain) were P1: ATGACTAAAAGCAATGGAGAA,
P1¢: GGTACCTGTGACAAGAC; P2: GAATGGCGGCGCTAGA-
TAGT, P2¢: CCACATTATTACTGCTACCAG; P3: GTTTAAAAC-
CAACTATGAGAAG, P3¢: ACCTTGAAGAGGTCCCCAGA; P4:
GCTCTGGGGACCTCTTCAAG, P4¢: TCTCAGTTTCATTGTCC-
TGTGC. PCR was carried out using Taq Platinum Master Mix
(Invitrogen) following the manufacturer’s instructions. PCR ampli-
ﬁcation products were resolved on 1% agarose gels, and electroph-
oretic bands were isolated using Concert Rapid Gel Extraction
System (Life Technologies, Barcelona, Spain). The puriﬁed
ampliﬁcation product was sequenced in the Genomic Service
(Universidad del Paı ´s Vasco, Spain). Primers P4 and P4¢ were used
for sense and antisense sequencing, respectively, and sequence
analysis was carried out using EditView software.
Quantiﬁcation of EAAT1ex9skip in different brain regions
Glutamate transporters EAAT1 and the splicing variant EAAT1ex9s-
kip were analysed by real-time quantitative RT-PCR, following the
recommendations of User Bulletin 2 (Applied Biosystems, Madrid,
Spain). Primers were designed using PrimerExpress software
(Applied Biosystems). Analysis of gene expression was performed,
starting with 20 ng reverse-transcribed total RNA with 200 nM
forward and reverse primers (High Puriﬁcation Salt Free, Genotek)
in a ﬁnal volume of 20 lL, using the Platinum SYBR Green qPCR
SuperMix UDG (Invitrogen) in an ABI PRISM 7000 Sequence
Detection System instrument (Applied Biosystems). Primers used
were: forward 5¢-CGAAGCCATCATGAGACTGGTA-3¢ and
reverse 5¢-TCCCAGCAATCAGGAAGAGAA-3¢ for EAAT1 ampli-
ﬁcation; and forward 5¢-TGCCCTCTATGAGGCTTTGG-3¢ and
reverse 5¢-GTCCGGAGGCGATCCCT-3¢ for EAAT1ex9skip ampli-
ﬁcation. Duplicate PCR reactions were carried out for each cDNA
sample and the standard deviations of the cycle threshold (Ct) values
considered were £ 0.38. We veriﬁed that the generated ﬂuorescence
was not overestimated by contamination resulting from residual
genomic DNA ampliﬁcation (using RT negative controls), primer
dimer formation or external DNA contamination (no template
controls). PCR products were subjected to a dissociation protocol to
ensure that a single amplicon of the expected melting temperature
was obtained. To quantify EAAT1 transcript concentrations in tissue
samples accurately, normal and variant clones were generated to act
as standards in the assay. Concentration of DNA standards was
assayed by spectrophotometry and agarose gel analysis and
subsequently, serial 10-fold dilutions were made with 60 pg DNA
per PCR reaction (r ‡ 0.99). The amount of each transcript was
calculated by plotting the results of the sample against the standard
curves. EAAT1ex9skip values are reported as percentage expression
of total EAAT1 transcripts. All results are expressed as mean ± SEM.
Cloning and transfection
cDNA amplicons encoding EAAT1 and the EAAT1 exon 9 skipping
splice variant were obtained by RT-PCR from human optic nerve
RNA using the following primer pair: forward: 5¢-CCTGACATG-
ACTAAAAGCAATG-3¢; reverse: 5¢-GTCTACATCTTGGTTT-
CACTGT-3¢. PCR was carried out with the Taq Platinum Master
Mix (Invitrogen) using an annealing temperature of 55 C and an
elongation time of 2 min for 35 cycles. The PCR reaction was
puriﬁed using the GenElute PCR DNA puriﬁcation kit (Sigma,
Madrid, Spain) and ligated into the pTARGET vector (Promega
Corporation, Madison, WI, USA). The eGFP vector (Clontech,
Madrid, Spain) was co-transfected with EAAT1 and EAAT1ex9skip
vectors, then used as an internal control of transfection efﬁciency.
For functional uptake experiments, EAAT1 and EAAT1ex9skip
vectors were co-transfected with pTARGET vector to normalize the
amount of DNA transfected. Transient transfections into HEK293
cells were carried out using LipofectAMINE Plus reagent (Invitro-
gen), following the manufacturer’s instructions. Cells were grown
on polylysine-coated glass coverslips, and maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum at 37 Ci naC O 2 incubator.
Immunocytochemistry
At 3–4 days after transfection, cells were washed with phosphate-
buffered saline (PBS), ﬁxed in 4% paraformaldehyde for 20 min,
permeabilized in methanol at )20 C for 10 min and pre-incubated
(1 h) with 4% normal goat serum in PBS. Immunostaining for
EAAT1 was carried out using an antibody (A522, 1 lg/mL)
generously provided by Dr N. C. Danbolt (University of Oslo).
The GRP78 antibody was from Santa Cruz Biotechnology (10 lg/
mL; sc-1051, Santa Cruz, CA, USA). Incubation with primary
antibodies was carried out overnight at 4 C. Binding of primary
antibodies was viewed with Alexa Fluor 488 goat anti-rabbit
secondary antibody (1 : 200; Molecular Probes, Eugene, OR, USA)
and biotinylated horse anti-goat secondary antibody (1 : 200; Vector
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Texas Red (1 : 100; Molecular Probes).
Western blot analysis
Glutamate transporter protein levels were determined in homogen-
ates of cells collected 3–4 days after transfection. Cell lysates were
size separated by 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE), transferred to nitrocellulose ﬁlters
(Amersham Pharmacia Biotech, Madrid, Spain), and incubated with
antibodies directed against the N-terminal portion of EAAT1 (1 lg/
mL; sc-15316, Santa Cruz Biotechnology) and green ﬂuorescence
protein (GFP) (0.4 lg/mL; Roche Diagnostics, Barcelona, Spain).
Primary antibodies were detected with anti-rabbit or anti-mouse
horseradish peroxidase-conjugated secondary antibodies (Sigma).
Immunosignals were visualized using SuperSignal West Dura
Chemiluminescent Substrate (Pierce, Rockford, IL, USA). Protein
band densitometry was carried out using Scion Image for Windows
(Scion, Frederick, MD, USA), and GFP immunoreactivity was used
to normalize transfection efﬁciency.
Glutamate uptake assay
Sodium-dependent glutamate uptake was carried out 3–4 days after
transfection, using transiently-transfected HEK293 cells. Cells were
plated in polylysine-coated, 96-well plates and incubated for 5 min at
37 C with 0.1 nM [
3H]glutamic acid (Amersham Pharmacia Biotech,
speciﬁc activity, SA: 40–50 Ci/mM) and L-glutamate acid (Sigma),
with ﬁnal glutamate concentrations ranging from 1 to 250 lM in a
saline buffer (assay buffer: 140 mM NaCl, 5 mM KCl, 2 mM MgCl2,
2m M CaCl2, 4,5 g/L glucose and 10 mM HEPES, pH 7.4). The
reaction was stopped by the addition of 2 mML-glutamate in ice-cold
assaybuffer,followedbytworapidwasheswithice-coldassaybuffer.
Net high-afﬁnity uptake was determined by subtracting no-sodium
blanks, where NaCl was replaced with choline chloride, from the
uptake in the presence of sodium, and expressed as picomoles of
glutamate/microgram protein/5 minutes. Uptake data were plotted by
non-linearregressionusingPrismsoftware(GraphPADSoftware,San
Diego, CA, USA). Km and Vmax values were determined using the
Eadie–Hofstee transformation. Data are expressed as a mean ± SEM
of at least three independent experiments carried out in triplicate.
Statistical analysis
Statistical comparisons were made by two-tailed non-paired Stu-
dent’s t-test using the Microsoft Excel 11.0 software for Macintosh.
Results
Molecular cloning of EAAT1ex9skip
We ampliﬁed the EAAT1 coding region from human optic
nerve, and we obtained the expected 1629 bp product,
together with a smaller sized transcript. To identify the latter,
we carried out several PCRs using inner primers that
ampliﬁed EAAT1 in four fragments (Fig. 1a). We observed
that the lower band was located in the 3¢ end of EAAT1
cDNA (Fragment 4, Fig. 1b). Isolation and sequencing of the
band revealed that this product was an alternatively spliced
variant of EAAT1 that lacked exon 9 and hence, we named it
EAAT1ex9skip (GenBank accession number AY954110).
Therefore, this is a different splice variant of the rat
GLAST1-a isoform which lacks exon 3 (Huggett et al.
2000). EAAT1 exon 9 comprises 145 bp and thus, its
omission does not alter the RNA reading frame. As a result,
the predicted amino acid sequence of EAAT1ex9skip is
identical to EAAT1, except for the lack of a 45 amino acid
extracellular motif near the carboxy terminal end (Fig. 1c).
EAAT1ex9skip expression in human brain
To establish whether EAAT1ex9skip expression is restricted
solely to the human optic nerve, we designed speciﬁc primers
for this variant and carried out quantitative RT-PCR in three
control subjects, using total RNA extracted from different
brain regions (cerebellum, corpus callosum, hippocampus,
cortex and optic nerve). We ﬁrst veriﬁed that EAAT1ex9skip
primers did not detect the full-length EAAT1 cDNA in 45
PCR cycles. We also quantiﬁed EAAT1 RNA to normalize
EAAT1ex9skip expression in the different samples. This
analysis revealed that EAAT1ex9skip mRNA was present in
all the areas studied (p<0.01) and that the relative levels of
EAAT1ex9skip mRNA range from 8% to 19% of EAAT1
mRNA; the hippocampus and cortex were the regions where
it was most and least abundant, respectively (Fig. 2). These
data indicate that the EAAT1ex9skip variant is widely
expressed throughout the human brain.
Functional expression of EAAT1 and EAAT1ex9skip in
HEK293 cells
The coding region of EAAT1 and EAAT1ex9skip forms were
cloned from human optic nerve cDNA, and functional
characterization was carried out by transient expression in
HEK293cells.Immunocytochemistrywithaspeciﬁcantibody
revealed that the full-length EAAT1 protein was predomin-
antly localized in the plasma membrane (Fig. 3a), a ﬁnding
consistent with previous studies (Huggett et al. 2002). In
contrast,cellsexpressingtheEAAT1ex9skipvariantpresented
a cytoplasmic immunoreactivity, and mock-transfected cells
showed no staining at all. To test whether the EAAT1ex9skip
variant is retained in the ER, we double-stained cells for the
78 kDa glucose-regulated protein (GRP78), a chaperone
protein located in the ER. GRP78 did not overlap with the
full-length EAAT1, although it did co-localize extensively
with the EAAT1ex9skip variant (Fig. 3a, right panel).
These data indicate that the EAAT1ex9skip splice variant
resides in the ER.
The function of these glutamate transporter forms was also
examined by measuring Na
+-dependent glutamate transport
in transiently transfected HEK293 cells. Expression of the
full-length EAAT1 protein led to a three to fourfold increase
in glutamate transport compared with uptake in cells
transfected with vector alone (Fig. 3b). Kinetic parameters
Vmax and Km were comparable with those determined in
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in vitro model. Interestingly, EAAT1ex9skip transfected cells
did not show glutamate transport above endogenous levels, a
ﬁnding which is consistent with the EAAT1ex9skip protein
localization in the ER.
Dominant-negative modulation of EAAT1ex9skip
variant
Western blot analysis revealed expression of EAAT1 protein
in cells transfected with either EAAT1 isoform, whereas no
signal was observed in cells transfected with vector alone
(Fig. 4a). Under our conditions, EAAT1 antibody recognized
bands of approximately 200 kDa, corresponding to multim-
ers (Danbolt 2001). EAAT1 migrated as a major band of
approximately 215 kDa and an adjacent, lower-sized band,
most likely representing a partially glycosylated species
(Schulte and Stoffel 1995). In contrast, the EAAT1ex9skip
variant migrated as a single 160 kDa band. This size
difference between full-length EAAT1 and EAAT1ex9skip
may be due to a lack of glycosylation of the spliced form, in
addition to the 45 amino acids omitted; this is suggested by
its localization in the ER, which indicates a low degree of
Fig. 2 Quantiﬁcation of EAAT1ex9skip mRNA in human brain. Histo-
gram shows proportion of EAAT1ex9skip variant in different brain
regions of three control subjects, as measured by real-time RT-PCR.
The relative contribution of EAAT1ex9skip variant to total EAAT1
transcripts in cerebellum, corpus callosum, hippocampus, optic nerve
andcortexwas15.07 ± 2.01,15.88 ± 6.41,19.14 ± 5.45,14.36 ± 6.07
and 8.79 ± 0.74, respectively. Data are expressed as mean ± SEM
values; *p<0.01.
Fig. 1 Identiﬁcation of EAAT1ex9skip variant. (a) Schematic repre-
sentation of EAAT1 cDNA coding region. P1–P4 and P1¢–P4¢ indicate
the primers used for ampliﬁcation (see Materials and methods). (b)
PCR analysis of human EAAT1. Ampliﬁcation with P4–P4¢ primers
(fragment 4) yields two products in optic nerve RNA. The size of the
expected amplicon is 526 bp long and includes exons 8–10, while the
shorter band has 391 bp and skips exon 9. (c) Topological model of
human EAAT1 (Seal et al. 2000). The loss of exon 9 removes the grey
region of EAAT1 that represents amino acids 430–474, and substi-
tutes leucine 475 for an arginine residue. Bold residues indicate
domain involved in post-translational processing and grey boxes show
relevant amino acids.
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tive bands showed that EAAT1ex9skip variant expression
was signiﬁcantly reduced compared with full-length EAAT1
expression (29.4 ± 8.7%; Fig. 4b). This effect is not due to
dissimilar protein translation efﬁciencies, as cells were also
co-transfected with 0.2 lg eGFP vector, and GFP immuno-
reactivity was used to normalize translation efﬁciencies.
To test whether this novel EAAT1 splice variant may
modulate EAAT1 function, equal quantities of EAAT1 and
EAAT1ex9skip plasmids (1 lg each) were co-transfected into
HEK293 cells. Both proteins were detected concurrently by
western blot (Fig. 4b), although there was noticeably less
EAAT1 protein in co-transfected cells compared with cells
transfected with EAAT1 plasmid alone. Moreover,
co-transfection of EAAT1 with increasing amounts of
EAAT1ex9skip resulted in dose-dependent inhibition of
glutamate uptake. Taking into consideration endogenous
transport in HEK293 cells, the level of inhibition of glutamate
uptake reached 44% when both EAAT1 isoforms were
co-transfected in the same proportion (Fig. 4c).
Discussion
In this study we identiﬁed a novel short form of human
EAAT1 which we named EAAT1ex9skip. This form is
generated from alternative splicing of exon 9 of the Slc1a3
gene, leading to an in-frame deletion of exon 9 in the EAAT1
mRNA. Using RT-PCR, we found that the EAAT1ex9skip
transcript has a widespread distribution and moderate
expression levels in post-mortem human brain tissue. Finally,
(a)
(b)
Fig. 3 Expression and functional characterization of EAAT1 isoforms
in HEK293 transfected cells. (a) Fluorescence immunostaining for
EAAT1 revealed different subcellular localization of EAAT1 and
EAAT1ex9skip forms. EAAT1 (green) is expressed at the plasma
membrane and does not overlap with staining for GRP78 (red), a
protein expressed in the endoplasmic reticulum. In contrast, EAA-
T1ex9skip co-localizes with GRP78 expression, indicating that this
variant is retained in the endoplasmic reticulum. Representative
confocal images of three independent experiments. Scale bar ¼
10 lm. (b) Glutamate uptake was analysed in transfected cells, using
100 nM of L-[H
3]-glutamic acid in the presence of increasing concen-
trations of unlabelled substrate, at 37 C for 5 min. EAAT1ex9skip did
not show any glutamate transport above endogenous levels. EAAT1
uptake velocity (pM/lg protein/5 min) and Km (lM) values were
23.5 ± 1.5 and 27.5 ± 2.3, respectively (right panel). Data points
represent the average of three independent experiments in triplicate.
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HEK293 cells that the EAAT1ex9skip transcript is translated
into a protein, although at lower levels than full-length
EAAT1. However, it does not retain glutamate uptake
activity and it exerts a dominant-negative effect over the
full-length EAAT1 protein.
EAAT1 exon 9 encodes 45 amino acids (430–475) near
the C-terminal (see Fig. 1c). This region is involved in
determining functional differences between EAAT1 and
EAAT2 subtypes (Mitrovic et al. 1998); it contains arginine
motifs involved in the post-translational processing and
endoplasmic retention signal of the EAAT2 protein, as well
as an upstream leucine-rich motif that is required for the
suppression of this signal (Kalandadze et al. 2004). Since
members in the glutamate transporter family share a high
degree of homology in this region, they may also have
common mechanisms for proper post-translational matur-
ation. Interestingly, the EAAT1ex9skip variant lacks the
upstream leucine-rich motif that lies within residues 451–475
of the full-length EAAT1 transporter and is coded by exon 9.
However, the arginine motif (amino acids 477 and 479) is
located in exon 10 and is therefore retained by the
EAAT1ex9skip variant. As a consequence, this isoform
lacks an extracellular domain, which is potentially essential
for ER departure.
Consistent with this, we found that EAAT1ex9skip
co-localized with the ER chaperone GRP78, as opposed to
EAAT1, which is expressed mostly in the plasma membrane.
Thus, retention of EAAT1ex9skip in the ER may eventually
target this protein for degradation (Hurtley and Helenius
1989). These results, together with previous ﬁndings
(Kalandadze et al. 2004), indicate that glutamate transporters
EAAT1 and EAAT2 share similar mechanisms for post-
translational maturation, and that EAAT1 exon 9 is required
for departure of EAAT1 transporter from the ER and for its
forward trafﬁcking through the secretory pathway. Similarly,
truncating the C-terminal domain of metabotropic glutamate
receptor mGluR1, or the dopamine receptor D2, results in
unmasking an ER retention signal, leading to the retained
expression of these alternative splice products in the ER
(Chan et al. 2001; Prou et al. 2001).
The dominant-negative effect that EAAT1ex9skip exerts
over EAAT1 could be explained by the oligomeric structure
of glutamate transporters (Haugeto et al. 1996; Kavanaugh
1998; Eskandari et al. 2000). Indeed, the function and
protein synthesis of full-length EAAT2 is negatively modu-
lated by splice variants which undergo rapid degradation (Lin
et al. 1998; Guo et al. 2002). However, little is known about
the mechanisms implicated in glutamate transporter modu-
lation by splice variants. In line with previous studies, we
observed that expression of EAAT1ex9skip was lower than
full-length EAAT1, likely due to instability of the truncated
protein. Moreover, we found that EAAT1ex9skip reduced
EAAT1 expression and function. Altogether, these results
suggest that inhibition of EAAT1 by the EAAT1ex9skip
variant is due to a protein–protein interaction in the ER that,
in turn, leads to a reduction in mature EAAT1 expression in
(a)
(b)
(c)
Fig. 4 Dominant-negative effect of EAAT1ex9skip variant over EAAT1
glutamate transporter function. (a) Western blot analysis of HEK293
cells transfected with 1 lg of EAAT1 isoforms plus 0.2 lg green
ﬂuorescent protein (GFP) vector, which was used as an internal control
of transfection efﬁciency. (b) Histogram represents the average density
of EAAT1, normalized to GFP in transient transfected HEK293 cells
(n ¼ 3). EAAT1ex9skip protein has a lower expression level compared
with full-length EAAT1 (29.4 ± 8.7%; *p<0.05), and EAAT1 expres-
sion was reduced when both EAAT1 forms were co-transfected in
similar proportions (67.7 ± 23.9). (c) Modulation of EAAT1 glutamate
uptake by EAAT1ex9skip variant. Cells were transfected with 1 lgo f
EAAT1 cDNA and variable amounts of EAAT1ex9skip cDNA.
pTARGET vector was used to normalize for equal amounts of DNA
transfected. EAAT1 glutamate transport was inhibited in a dose-
dependent manner, reaching 44% inhibition when 1 lg of EAA-
T1ex9skip was co-transfected with EAAT1. Data points were obtained
by substracting the glutamate uptake in the absence of Na
+. Results
presented are means ± SEM of three independent experiments per-
formed in triplicate. Statistical signiﬁcance: *p<0.05, **p<0.005.
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full-length and truncated isoforms are probably retained in
the ER because they are incorrectly assembled and thus,
targeted for degradation (Hurtley and Helenius 1989; Klaus-
ner and Sitia 1990).
An important unresolved issue is whether EAAT splice
variants play a physiological or pathological role in the CNS.
It has been reported that aberrant RNA processing of EAAT2
is involved in the pathogenesis of amyotrophic lateral
sclerosis (Bai and Lipton 1998; Lin et al. 1998). However,
other studies do not support these ﬁndings and favour a
physiological function for the EAAT splice variants (Honig
et al. 2000; Flowers et al. 2001). Our data indicate that
EAAT1ex9skip is not necessarily related to pathogenic
events but rather, plays a physiological role in the CNS, as
revealed by its relatively high expression throughout the
human CNS. We postulate that the functional signiﬁcance of
EAAT1ex9skip may reside in its ability to modulate EAAT1
expression and activity at the post-translational processing
level. Nevertheless, aberrant EAAT1ex9skip expression
could potentially lead to abnormal regulation of glutamate
homeostasis, which is involved in several neurological
disorders (Danbolt 2001).
In summary, we have characterized a novel human EAAT1
splice variant that negatively modulates the expression and
functionofthisglutamate transporter.Thefactthat thisvariant
iswidelyexpressedingreyandwhitemattermayberelevantto
glutamate homeostasis and excitotoxicity, a common event in
neurodegenerative and demyelinating diseases.
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